Advance Block: Understanding the Bearish Reversal Pattern

An advance block is a bearish reversal pattern in candlestick charts, signaling potential trend shifts. Learn its ...

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.45% on an annualized basis producing an average annual return of 15.15%. Currently, AbbVie has a market capitalization of ...

AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

AbbVie: The Dividend Does Not Lie

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...

What Can Trigger A Breakout In Abbvie Stock?

These robust surges underscore AbbVie’s ability for swift gains, indicating that upcoming catalysts could propel the stock to ...

AbbVie's Rally Looks Convincing -- But The Stock Is Not A Bargain

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...
news.bloomberglaw

AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero

AbbVie Inc. and Neurocrine Biosciences Inc. agreed to end their federal lawsuit alleging Hetero Labs Ltd.'s proposed copies of the endometriosis drug Orilissa infringe a newer formulation patent, ...
Nasdaq

ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?

AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have strong leadership positions in immunology and oncology areas. While AbbVie ...
Nasdaq

Is AbbVie a Millionaire Maker?

AbbVie is a pharmaceutical company with a focus on immunology, oncology, neuroscience, and aesthetics. The company's third-quarter earnings were down materially year over year, but it raised its ...